<?xml version="1.0" encoding="UTF-8"?>
<ref id="jcp29785-bib-0027">
 <mixed-citation publication-type="journal" id="jcp29785-cit-0027">
  <string-name>
   <surname>Ison</surname>, 
   <given-names>M. G.</given-names>
  </string-name>, 
  <string-name>
   <surname>Portsmouth</surname>, 
   <given-names>S.</given-names>
  </string-name>, 
  <string-name>
   <surname>Yoshida</surname>, 
   <given-names>Y.</given-names>
  </string-name>, 
  <string-name>
   <surname>Shishido</surname>, 
   <given-names>T.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hayden</surname>, 
   <given-names>F.</given-names>
  </string-name>, &amp; 
  <string-name>
   <surname>Uehara</surname>, 
   <given-names>T.</given-names>
  </string-name> (
  <year>2018</year>). 
  <article-title>LB16. Phase 3 trial of Baloxavir Marboxil in high‐risk influenza patients (CAPSTONE‐2 study)</article-title>. 
  <source xml:lang="en">Open Forum Infectious Disease</source>, 
  <volume>5</volume>(
  <issue>Suppl. 1</issue>), 
  <fpage>S764</fpage>–
  <lpage>S765</lpage>.
 </mixed-citation>
</ref>
